Depressive Disorder News and Research

RSS

Vanda to initiate tasimelteon Phase IIb/III clinical trial in Major Depressive Disorder

Vanda Pharmaceuticals Inc. today announced its plans to initiate a Phase IIb/III clinical trial of tasimelteon in patients with Major Depressive Disorder (MDD). The trial is expected to begin during the second half of 2011. Tasimelteon is currently being evaluated in Phase III clinical trials for the treatment of Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals without light perception.

31 Mar 2011

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has enrolled 33 percent of the total projected patients required for its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).

24 Mar 2011

Euthymics Bioscience initiates EB-1010 phase 2b/3a TRIADE clinical trial for major depressive disorder

Euthymics Bioscience, Inc. today announced the initiation of an advanced clinical study of its lead product candidate EB-1010 for the treatment of major depressive disorder (MDD). The TRIADE (Triple Reuptake Inhibitor Anti-Depressant Effects) trial is a phase 2b/3a clinical trial designed to assess the safety and efficacy of EB-1010, a novel serotonin-preferring triple reuptake inhibitor.

14 Mar 2011

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Neuralstem, Inc. announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform. This phase of the trial is in healthy volunteers and seeks to determine the maximum tolerated single dose.

2 Mar 2011

Preliminary top-line results from cariprazine 8-week Phase II trial against major depressive disorder

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel, investigational antipsychotic agent cariprazine as adjunctive therapy in major depressive disorder.

28 Feb 2011

Forest Labs enters definitive merger agreement to acquire Clinical Data

Forest Laboratories, Inc. and Clinical Data, Inc. today announced that they have entered into a definitive merger agreement pursuant to which Forest will acquire Clinical Data, a specialty pharmaceutical company focused on the development of first-in-class and best-in-category therapeutics, for $30.00 per share in cash plus contingent consideration of up to $6.00 per share that may be paid upon achievement of certain commercial milestones related to Viibryd.

22 Feb 2011

Grief after loss of a significant other may become a disease

In the current issue of Psychotherapy and Psychosomatics, a group of French investigators headed by Guy Chouinard presents data that indicate that grief after the loss of a significant other may become a disease. One issue facing the DSM-V in the revision of the criteria for major depressive disorder (MDD) concerns bereavement criterion E, which often leads to exclusion from major depressive episode (MDE).

16 Feb 2011

WINCS detects and measures serotonin levels in brain through deep brain stimulation

Mayo Clinic researchers have concluded that, through deep brain stimulation, a Wireless Instantaneous Neurotransmitter Concentration System (WINCS) can detect and measure serotonin levels in the brain. The findings suggest that in the future such measurements of serotonin may help establish a therapeutic mechanism of deep brain stimulation for psychiatric disease.

16 Feb 2011

New study finds peer support greatly reduces symptoms of depression

Peer support offers promise as an effective, low-cost tool for fighting depression, a new study by the VA Ann Arbor Healthcare System and University of Michigan Health System finds.

16 Feb 2011

L-methylfolate in combination with antidepressant drug helps major depressive disorder patients

Data published in the January issue of Innovations in Clinical Neuroscience, www.psychiatrymmc.com, suggest when L-methylfolate, a medical food available commercially as Deplin®, and by prescription, is used for dietary management of depression in combination with an antidepressant drug at the start of depression therapy, it results in significantly more patients experiencing major improvement and more rapid improvement than antidepressant monotherapy alone.

10 Feb 2011

Clinical Data reports $2.0 million revenue for third quarter 2011

Clinical Data, Inc. today announced operational and financial results for the third fiscal quarter ended December 31, 2010. The Company received approval from the U.S. Food and Drug Administration (FDA) of Viibryd™ for the treatment of adults with major depressive disorder (MDD) on January 21, 2011.

9 Feb 2011

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

CeNeRx BioPharma, Inc., a clinical-stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced FDA approval of its IND and reported the first clinical results in humans for CXB909, a novel agent that has demonstrated utility in preclinical models of neuroprotection and neurodegenerative disorders.

9 Feb 2011

ScinoPharm to be Clinical Data's sole API supplier of vilazodone hydrochloride during Viibryd's launch

ScinoPharm, a leading active pharmaceutical ingredient (API) and contract research and manufacturing (CRAM) service provider to the global pharmaceutical and biotechnology industry, will provide commercial manufacturing service of vilazodone hydrochloride active pharmaceutical ingredient (API) for Clinical Data, Inc.'s Viibryd™, a new drug entity recently approved by the United States Food and Drug Administration.

8 Feb 2011

Study identifies genetic variation linked with increased risk of major depression

Numerous studies have shown that the brain molecule neuropeptide Y (NPY) helps to restore calm after stressful events. A team of University of Michigan-led researchers has now found that people whose genes predispose them to produce lower levels of NPY are more responsive to negative stimuli in key brain circuits related to emotion - and are therefore less resilient in the face of stress and may be at higher risk for developing a major depressive disorder.

8 Feb 2011

NIMH awards two BUSM members with BRAINS grant for innovative research on mental disorders

Two Boston University School of Medicine faculty members, Pietro Cottone, PhD, an assistant professor of pharmacology and psychiatry and Michael Silverstein, MD, an associate professor of pediatrics, were each awarded the prestigious National Institute of Mental Health Biobehavioral Research Awards for Innovative New Scientisits grant with ten other investigators from around the country.

7 Feb 2011

AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder

AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.

7 Feb 2011

WINCS device can detect and measure serotonin levels in brain: Mayo Clinic

Mayo Clinic researchers have concluded that, through deep brain stimulation, a Wireless Instantaneous Neurotransmitter Concentration System can detect and measure serotonin levels in the brain. The findings suggest that in the future such measurements of serotonin may help establish a therapeutic mechanism of deep brain stimulation for psychiatric disease.

5 Feb 2011

Depressive Disorder News and Research

Vanda to initiate tasimelteon Phase IIb/III clinical trial in Major Depressive Disorder

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Euthymics Bioscience initiates EB-1010 phase 2b/3a TRIADE clinical trial for major depressive disorder

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Preliminary top-line results from cariprazine 8-week Phase II trial against major depressive disorder

Forest Labs enters definitive merger agreement to acquire Clinical Data

Grief after loss of a significant other may become a disease

WINCS detects and measures serotonin levels in brain through deep brain stimulation

New study finds peer support greatly reduces symptoms of depression

L-methylfolate in combination with antidepressant drug helps major depressive disorder patients

Clinical Data reports $2.0 million revenue for third quarter 2011

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

ScinoPharm to be Clinical Data's sole API supplier of vilazodone hydrochloride during Viibryd's launch

Study identifies genetic variation linked with increased risk of major depression

NIMH awards two BUSM members with BRAINS grant for innovative research on mental disorders

AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder

WINCS device can detect and measure serotonin levels in brain: Mayo Clinic

FDA approves Clinical Data's Viibryd for major depressive disorder

PGxHealth receives FDA approval for Viibryd tablets to treat major depressive disorder

Health Canada approves Labopharm's OLEPTRO for treatment of Major Depressive Disorder

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News